Midwest Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Midwest Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.5K	Buy	18,115 +7,980	+79%	+$26.6K	0.02%	135
2026 Q1	$31.1K	Hold	10,135	–	–	0.01%	126
2025 Q4	$41.5K	Hold	10,135	–	–	0.02%	123
2025 Q3	$49.5K	Sell	10,135 -1,884	-16%	-$9.89K	0.02%	121
2025 Q2	$60.8K	Hold	12,019	–	–	0.03%	114
2025 Q1	$63.6K	Hold	12,019	–	–	0.04%	108
2024 Q4	$81.2K	Hold	12,019	–	–	0.05%	111
2024 Q3	$79K	Hold	12,019	–	–	0.05%	109
2024 Q2	$90K	Buy	+12,019	New	+$105K	0.06%	105

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Midwest Financial Group's RXRX Position: Q2 2026 in Review

Midwest Financial Group increased its Recursion Pharmaceuticals (RXRX) stake by 79% in Q2 2026, buying an estimated $26.6K and bringing the position to 18,115 shares worth $66.5K. The position accounts for 0.02% of the portfolio, ranked #135.

Midwest Financial Group first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $90K in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Midwest Financial Group held 18,115 shares of Recursion Pharmaceuticals worth $66.5K as of Q2 2026.
Midwest Financial Group bought 7,980 Recursion Pharmaceuticals shares in Q2 2026, an estimated $26.6K.
Recursion Pharmaceuticals made up 0.02% of Midwest Financial Group's portfolio in Q2 2026, its #135 holding.
Midwest Financial Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Midwest Financial Group's Recursion Pharmaceuticals position peaked at $90K in Q2 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Midwest Financial Group's 13F filing for Q2 2026, filed 21 Jul 2026.